AbbVie Inc. $ABBV is Commonwealth Retirement Investments LLC’s 4th Largest Position

Commonwealth Retirement Investments LLC raised its holdings in AbbVie Inc. (NYSE:ABBV) by 4.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,296 shares of the company’s stock after buying an additional 2,267 shares during the period. AbbVie makes up approximately 3.7% of Commonwealth Retirement Investments LLC’s portfolio, making the stock its 4th largest position. Commonwealth Retirement Investments LLC’s holdings in AbbVie were worth $9,707,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the 2nd quarter valued at about $25,000. TD Capital Management LLC boosted its stake in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the period. Abound Financial LLC purchased a new position in AbbVie in the first quarter worth approximately $30,000. Cypress Capital Management LLC WY purchased a new position in AbbVie in the first quarter worth approximately $35,000. Finally, Bear Mountain Capital Inc. lifted its stake in AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.25% of the stock is currently owned by company insiders.

AbbVie Price Performance

Shares of ABBV opened at $216.09 on Wednesday. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The stock has a market cap of $381.73 billion, a PE ratio of 102.90, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. The firm has a fifty day moving average price of $222.66 and a 200 day moving average price of $201.73.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 EPS. The business’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several recent analyst reports. Daiwa America raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. lifted their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday. UBS Group set a $251.00 price target on AbbVie in a report on Friday, October 3rd. Finally, Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $237.81.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.